Sugi Predict

Sugi Predict / Compounds / SCHEMBL6923874

SCHEMBL6923874

SCHEMBL6923874

COC1CCN(CC(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 3/20 0.47
▸ PIK3CD O00329 4/20 0.41
▸ CYP2D6 P10635 2/20 0.39
▸ KCNQ3 O43525 2/20 0.35
▸ KCNQ2 O43526 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TLR8 Q9NR97 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ NAMPT P43490 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16803019 0.88 PIK3CD (0.42) HRH3PIK3CDCYP2D6KCNQ3KCNQ2
SCHEMBL14706858 0.88 PIK3CD (0.42) HRH3PIK3CDCYP2D6KCNQ3KCNQ2
SCHEMBL22725369 0.88 PIK3CD (0.42) HRH3PIK3CDCYP2D6KCNQ3KCNQ2
SCHEMBL23560035 0.84 HRH3 (0.49) HRH3PIK3CDCYP2D6SMN1; SMN2MEN1
SCHEMBL4319496 0.83 HRH3 (0.36) HRH3KCNQ3KCNQ2KCNH2
SCHEMBL25086279 0.83 HRH3 (0.36) HRH3KCNQ3KCNQ2KCNH2
SCHEMBL357739 0.83 HRH3 (0.36) HRH3KCNQ3KCNQ2KCNH2
SCHEMBL11911609 0.82 HRH3 (0.38) HRH3MEN1KMT2ANAMPTKCNH2
SCHEMBL14706853 0.81 HRH3 (0.46) HRH3PIK3CDCYP2D6KCNQ3KCNQ2
SCHEMBL15806912 0.81 KCNH2 (0.34) HRH3TLR8TLR7ALDH1A1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122249-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-20 — — US disclosed
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY 2023-01-26 — — US disclosed
US-20210221796-A1 ANTIBACTERIAL COMPOUNDS BLACKSMITH MEDICINES, INC. 2021-07-22 — — US disclosed
WO-2021127278-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-06-24 — — WO disclosed
EP-3715343-A1 DIPHENYLAMINOPYRIMIDINE COMPOUND FOR INHIBITING KINASE ACTIVITY Shenzhen TargetRx, Inc. (CN) 2020-09-30 — — EP disclosed
WO-2020061375-A1 ANTIBACTERIAL COMPOUNDS FORGE THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 — — US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 — — US disclosed
US-9849135-B2 USP14 inhibitors for treating or preventing viral infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2017-12-26 — — US disclosed
EP-2528911-B1 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY HARVARD COLLEGE (US) 2017-10-25 — — EP disclosed
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity THE ASSAY DEPOT, INC. 2016-07-28 — — US disclosed
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2015-11-26 — — US disclosed
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-18 — — US disclosed
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2013-02-21 — — US disclosed
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MERCK SHARP & DOHME LLC 2012-05-10 — — US disclosed
WO-2011094545-A2 COMPOSITIONS AND METHODS FOR ENHANCING PROTEASOME ACTIVITY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210221796-A1 ANTIBACTERIAL COMPOUNDS SPOUT1, MRPL21, NRDC HRH3 3748/4885PIK3CD 913/4885CYP2D6 2814/4885
US-20150335652-A1 USP14 Inhibitors for Treating or Preventing Viral Infections USP14, USP1, USP13 HRH3 4043/4885PIK3CD 2896/4885CYP2D6 2987/4885
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 HRH3 4413/4885PIK3CD 2423/4885CYP2D6 4794/4885
US-20230026466-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 HRH3 2562/4885PIK3CD 1633/4885CYP2D6 4154/4885
US-20130045992-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSMB11, PSME3 HRH3 4417/4885PIK3CD 2348/4885CYP2D6 4779/4885
US-20160214989-A1 Compositions and Methods for Enhancing Proteasome Activity PSMG3, PSME3, PSMB11 HRH3 4413/4885PIK3CD 2423/4885CYP2D6 4794/4885
US-20140275169-A1 Combination Therapies for Enhancing Protein Degradation HSPA2, HSPBP1, HSPH1 HRH3 3703/4885PIK3CD 4313/4885CYP2D6 4802/4885
US-20230122249-A1 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS TLR7, TLR9, TLR1 HRH3 388/4885PIK3CD 1103/4885CYP2D6 3938/4885
US-20120114739-A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS MTOR, RICTOR, RPTOR HRH3 3422/4885PIK3CD 95/4885CYP2D6 3574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.